Bukwang Pharm Joins Project to Develop Digital Therapeutic for Schizophrenia
MOU with Samsung Medical Center and Blue Signum
Collaborate on all aspects of Affectus development
Bukwang Pharm will participate in a project led by Samsung Medical Center and mental wellness startup Blue Signum to develop a digital therapeutic aimed at improving social cognition in people with schizophrenia.
Bukwang Pharm said on October 22 that it had signed an MOU with Samsung Medical Center and Blue Signum on the 15th to jointly develop Affectus, a software medical device.
Officials pose for a commemorative photo after signing an MOU on the 15th to jointly develop Affectus, a software medical device designed to improve social cognition in people with schizophrenia. From left: Lee Jeyoung, CEO of Bukwang Pharmaceutical; Choi Jeongseok, professor at Samsung Medical Center; and Yoon Junghyun, CEO of BlueSignum. Bukwang Pharmaceutical
View original imageUnder the agreement, the three organizations will collaborate across all aspects of Affectus's development, including clinical development, product enhancement and regulatory approval, and clinical implementation and commercialization.
Through the agreement, Bukwang Pharm will combine its expertise in the central nervous system (CNS) field and experience commercializing pharmaceuticals with Samsung Medical Center's clinical research capabilities and Blue Signum's digital technology and product development capabilities. Building on their respective expertise, the organizations plan to work together to expand the clinical applicability of Affectus and develop it into a new treatment option in the future.
Affectus, a software medical device, is being developed to improve social cognition in people with schizophrenia. It is intended to support patients' daily lives and social reintegration through digital social cognition training. An exploratory clinical trial is currently underway at Samsung Medical Center.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Lee Jeyoung, CEO of Bukwang Pharm, said, "I am honored to take part in this meaningful project led by Samsung Medical Center. We will draw on Bukwang Pharm's expertise in the CNS field and work together to develop Affectus into a treatment option that can benefit patients."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.